Icosavax Inc

NASDAQ ICVX

Download Data

Icosavax Inc Current Liabilities to Total Liabilities Ratio 1 year YoY Change (%) for the year ending December 31, 2022: -31.55%

Icosavax Inc Current Liabilities to Total Liabilities Ratio 1 year YoY Change (%) is -31.55% for the year ending December 31, 2022, a -105.08% change year over year. The current liabilities to total liabilities ratio measures the proportion of a company's current liabilities in relation to its total liabilities. It is calculated by dividing current liabilities by total liabilities. This ratio provides insights into the percentage of a company's total liabilities that are classified as current liabilities. It helps evaluate the company's overall liability structure and the importance of short-term obligations in relation to total liabilities. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Icosavax Inc Current Liabilities to Total Liabilities Ratio for the year ending December 31, 2022 was 0.67, a -31.55% change year over year.
  • Icosavax Inc Current Liabilities to Total Liabilities Ratio for the year ending December 31, 2021 was 0.98, a 621.53% change year over year.
  • Icosavax Inc Current Liabilities to Total Liabilities Ratio for the year ending December 31, 2020 was 0.14, a 250.83% change year over year.
  • Icosavax Inc Current Liabilities to Total Liabilities Ratio for the year ending December 31, 2019 was 0.04.
NASDAQ: ICVX

Icosavax Inc

CEO Mr. Adam K. Simpson
IPO Date July 29, 2021
Location United States
Headquarters 1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees 60
Sector Healthcare
Industry Biotechnology
Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

NA

NA

DAWN

Day One Biopharmaceuticals Inc

NA

NA

ELDN

Eledon Pharmaceuticals Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

FRLN

Freeline Therapeutics Holdings Plc

NA

NA

AVRO

AVROBIO Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email